About

ABOUT US

Discover
HEMA Biologics

About HEMA Biologics

HEMA Biologics is dedicated to helping those living with the rarest bleeding disorders.

"Through our services and resources, we want patients living with hemophilia
with inhibitors or severe von Willebrand disease to have a positive disease
management experience."

OUR MISSION

Meeting the needs of those who need it most

HEMA Biologics is a privately held biopharmaceutical company focused on the rarest bleeding disorders.

Our goal is to meet the needs of patients living with these disorders, support the broader community that cares for them, and bring meaningful therapies and services to help better their daily lives.

OUR PRINCIPLES

A personal touch is at the heart of our company.

And it comes out in everything we do.

Highly focused on serving patients with the rarest bleeding disorders

Agile in responding to our customers’ needs and requests and relentless in finding solutions that work

Closely aligned and collaborative with our patients and partners

Empathetic to the needs of those living with a rare bleeding disorder

Persistent in our development of high-quality investigational therapies

OUR RESPONSIBILITY

We take our mission seriously

We believe that our focused approach can help advance our mission to improve the health and care for people living with the rarest bleeding disorders. We are committed to:

  • Upholding the highest ethical standards
  • Responding to our customers' needs
  • Pursuing solutions for patients, their families, and the healthcare professionals who care for them

Rooted in Europe, making a difference in the US

We take pride in the heritage of LFB SA, a French state-owned company and the developer and manufacturer of our investigational therapies.

LFB SA is an innovative European biopharmaceutical company dedicated to the development, manufacture, and safety of therapeutic proteins.

OUR HERITAGE

HEMA Biologics is excited to partner with LFB SA in the further development and potential commercialization of these therapies in the United States.